Ocean Biomedical: Shooting Upward, But Not Somewhere I Want To Be (Rating Upgrade) [Seeking Alpha]
Ocean Biomedical, Inc. (OCEA)
Company Research
Source: Seeking Alpha
The company remains in the translational phase of development, with efforts focused on targeting the carbohydrate modulator Chi3l1. The financial picture for Ocean Biomedical has not changed, and their poor filing compliance raises concerns about the company's operations. Topline Summary and Update There is a truism in biotech that an author on Seeking Alpha has to respect. Even if you're right about a stock, you're only right until you're wrong. With Ocean Biomedical, Inc. ( NASDAQ: OCEA my personal feelings were initially very negative, since they weren't yet to the spot in development where they would have any data, so there was essentially nothing to judge them by, realistically. From late August and for the rest of 2023, my article looked prophetic, as OCEA fell almost 90% into the depths of penny stock land. Then, almost out of nowhere, they've vaulted back into the microcap range, erasing a lot of my "prediction." You're right until you're wrong. Only in this case,
Show less
Read more
Impact Snapshot
Event Time:
OCEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCEA alerts
High impacting Ocean Biomedical, Inc. news events
Weekly update
A roundup of the hottest topics
OCEA
News
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KGlobeNewswire
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLGlobeNewswire
- Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting [Yahoo! Finance]Yahoo! Finance
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingGlobeNewswire
OCEA
Sec Filings
- 4/24/24 - Form 8-K
- 4/15/24 - Form 10-Q
- 4/15/24 - Form 10-Q/A
- OCEA's page on the SEC website